Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model.
Simonetti. Oriana O; Cirioni. Oscar O; Goteri. Gaia G; Lucarini. Guendalina G; Kamysz. Elżbieta E; Kamysz. Wojciech W; Orlando. Fiorenza F; Rizzetto. Giulio G; Molinelli. Elisa E; Morroni. Gianluca G; Ghiselli. Roberto R; Provinciali. Mauro M; Giacometti. Andrea A; Offidani. Annamaria A
Key Findings
- Topical and intraperitoneal LL‑37 increased re‑epithelialization and granulation tissue formation
- LL‑37 improved collagen organization and angiogenesis in infected wounds
- LL‑37 showed antimicrobial activity against MRSA in the mouse wound model
Practical Outcomes
- LL‑37 looks promising as a topical antimicrobial for tough infections like MRSA, but it’s only been tested in mice so far. Biohackers should wait for human safety and dosage data before trying it, though the study supports keeping an eye on LL‑37 for future wound‑care protocols.
Summary
In a mouse study, applying the natural peptide LL‑37 to MRSA‑infected wounds helped the skin heal faster, with better tissue formation and more blood vessels, suggesting it could be a useful future treatment for infected wounds.
Abstract
LL-37 is the only human antimicrobial peptide that belongs to the cathelicidins. The aim of the study was to evaluate the efficacy of LL-37 in the management of MRSA-infected surgical wounds in mice. A wound on the back of adult male BALB/c mice was made and inoculated with <i>Staphylococcus aureus</i>. Two control groups were formed (uninfected and not treated, C0; infected and not treated, C1) and six contaminated groups were treated, respectively, with: teicoplanin, LL-37, given topically and /or systemically. Histological examination of VEGF expression and micro-vessel density, and bacterial cultures of wound tissues, were performed. Histological examination of wounds in the group treated with topical and intraperitoneal LL-37 showed increased re-epithelialization, formation of the granulation tissue, collagen organization, and angiogenesis. Based on the mode of action, LL-37 has a potential future role in the management of infected wounds.
Study Information
pubmed
2021
2021-10-05T00:00:00.000Z
10.3390/antibiotics10101210
24
65